|
Name |
6-methoxyspirotryprostatin B
|
| Molecular Formula | C22H23N3O4 | |
| IUPAC Name* |
(5S,6S,9S)-6'-methoxy-6-(2-methylprop-1-enyl)spiro[1,7-diazatricyclo[7.3.0.03,7]dodec-3-ene-5,3'-1H-indole]-2,2',8-trione
|
|
| SMILES |
CC(=C[C@H]1[C@]2(C=C3N1C(=O)[C@@H]4CCCN4C3=O)C5=C(C=C(C=C5)OC)NC2=O)C
|
|
| InChI |
InChI=1S/C22H23N3O4/c1-12(2)9-18-22(14-7-6-13(29-3)10-15(14)23-21(22)28)11-17-19(26)24-8-4-5-16(24)20(27)25(17)18/h6-7,9-11,16,18H,4-5,8H2,1-3H3,(H,23,28)/t16-,18-,22-/m0/s1
|
|
| InChIKey |
UHQKDPCPFNXIDU-ZJBJCVSYSA-N
|
|
| Synonyms |
6-methoxyspirotryprostatin B; CHEBI:66707; (2S,3S,5aS)-5a,6,7,8-Tetrahydro-6'-methoxy-3-(2-methyl-1-propen-1-yl)spiro[5H,10H-dipyrrolo[1,2-a:1',2'-d]pyrazine-2(3H),3'-[3H]indole]-2',5,10(1'H)-trione; (2S,3S,5aS)-6'-methoxy-3-(2-methylprop-1-en-1-yl)-5a,6,7,8-tetrahydro-5H,10H-spiro[dipyrrolo[1,2-a:1',2'-d]pyrazine-2,3'-indole]-2',5,10(1'H)-trione; CHEMBL488302; Q27135329; (5S,6S,9S)-6'-methoxy-6-(2-methylprop-1-enyl)spiro[1,7-diazatricyclo[7.3.0.03,7]dodec-3-ene-5,3'-1H-indole]-2,2',8-trione
|
|
| CAS | NA | |
| PubChem CID | 24900164 | |
| ChEMBL ID | CHEMBL488302 |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 393.4 | ALogp: | 1.8 |
| HBD: | 1 | HBA: | 4 |
| Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 79.0 | Aromatic Rings: | 5 |
| Heavy Atoms: | 29 | QED Weighted: | 0.784 |
| Caco-2 Permeability: | -5.043 | MDCK Permeability: | 0.00001820 |
| Pgp-inhibitor: | 0.668 | Pgp-substrate: | 0.665 |
| Human Intestinal Absorption (HIA): | 0.007 | 20% Bioavailability (F20%): | 0.239 |
| 30% Bioavailability (F30%): | 0.945 |
| Blood-Brain-Barrier Penetration (BBB): | 0.948 | Plasma Protein Binding (PPB): | 85.81% |
| Volume Distribution (VD): | 1.036 | Fu: | 16.75% |
| CYP1A2-inhibitor: | 0.019 | CYP1A2-substrate: | 0.642 |
| CYP2C19-inhibitor: | 0.489 | CYP2C19-substrate: | 0.878 |
| CYP2C9-inhibitor: | 0.257 | CYP2C9-substrate: | 0.695 |
| CYP2D6-inhibitor: | 0.022 | CYP2D6-substrate: | 0.199 |
| CYP3A4-inhibitor: | 0.454 | CYP3A4-substrate: | 0.926 |
| Clearance (CL): | 7.943 | Half-life (T1/2): | 0.128 |
| hERG Blockers: | 0.026 | Human Hepatotoxicity (H-HT): | 0.951 |
| Drug-inuced Liver Injury (DILI): | 0.883 | AMES Toxicity: | 0.065 |
| Rat Oral Acute Toxicity: | 0.727 | Maximum Recommended Daily Dose: | 0.593 |
| Skin Sensitization: | 0.745 | Carcinogencity: | 0.692 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.007 |
| Respiratory Toxicity: | 0.529 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC002020 | ![]() |
0.653 | D06HBQ | ![]() |
0.287 | ||
| ENC005479 | ![]() |
0.537 | D0Q5NX | ![]() |
0.264 | ||
| ENC002274 | ![]() |
0.481 | D0U7GK | ![]() |
0.264 | ||
| ENC001060 | ![]() |
0.481 | D09OBB | ![]() |
0.264 | ||
| ENC001958 | ![]() |
0.477 | D02DPU | ![]() |
0.260 | ||
| ENC003264 | ![]() |
0.477 | D0A3ZU | ![]() |
0.259 | ||
| ENC003265 | ![]() |
0.465 | D0L0ZF | ![]() |
0.242 | ||
| ENC003322 | ![]() |
0.445 | D06YFA | ![]() |
0.242 | ||
| ENC003281 | ![]() |
0.439 | D0I5HF | ![]() |
0.236 | ||
| ENC002519 | ![]() |
0.434 | D00XHD | ![]() |
0.234 | ||